Rani Therapeutics Holdings, Inc.
NASDAQ:RANIBiotechnology
-$0.04 today
- Market cap
- $52.19M
- Beta
- 0.76
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.16
Volume 0.23M
Average 1.15M
RANI Other Financing Activities
Financing cash flows not reported separately.
Rani Therapeutics Holdings, Inc.NASDAQ: RANI
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities grows, but more slowly than its trailing trend
Q1 FY2026 other financing activities of $32K (cash outflow) rose 39.1% year over year, behind the +3963.4% change in trailing-twelve-month other financing activities. Sequentially, it rose 52.4% from the prior quarter. Over 3 fiscal years it compounded at -59.5% a year.
Context
- Other financing activities amounted to 3.6% of revenue in FY2025, down 1.0 pp from a year earlier.
- Other financing activities grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +39.1% toward the trailing-twelve-month pace of +3963.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (59K) USD
- Year-over-year change
- -25.5%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (59K) | -25.5% |
| FY2024 | 2024-12-31 | (47K) | +71.0% |
| FY2023 | 2023-12-31 | (162K) | +81.7% |
| FY2022 | 2022-12-31 | (886K) | -3507.7% |
| FY2021 | 2021-12-31 | 26K | — |
Other Financing Activities vs competitors
How RANI compares with its peers on the latest reported figures
- Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +3963.4% is the highest of 9, against a peer median of -25.9%.
- Other financing activities amounts to 86.6% of revenue for RANI, versus a peer median of 4.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $94.39M USD | +3652.5% | — | 537.7% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $9.92M USD | -9.8% | — | — |
| LTM Mar 2026 | $2.74M USD | +3963.4% | -59.5% | 86.6% | |
| LTM Mar 2026 | $1.42M USD | -42.0% | +149.9% | 4.1% | |
| LTM Mar 2026 | $599.2K USD | +649.0% | — | 33.6% | |
| LTM Mar 2026 | CHF 413.44K CHF | -102.6% | — | — | |
| LTM Mar 2026 | $25K USD | +31.6% | — | 4.8% | |
| FY2025 | €0 EUR | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | -100.0% | — | — | |
| Peer median (excluding RANI) | — | -25.9% | +149.9% | 4.8% | |
Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (8.33M) | (63.34M) | (33.97M) | (56.58M) | (29.67M) |
| Depreciation & Amortization | 497K | 548K | 822K | 1.03M | 900K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.6M | 15.78M | 19.01M | 16.03M | 11.8M |
| Change in Working Capital | (3.43M) | 509K | (2.14M) | (544K) | 6.96M |
| Accounts Receivables | 0 | 0 | 0 | (428K) | (1.61M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 543K | 163K | (595K) | 711K | (1.05M) |
| Other Working Capital | (3.97M) | 346K | (1.55M) | (827K) | 9.62M |
| Other Non-Cash Items | (43.58M) | (10K) | (34.96M) | 4.57M | (8.7M) |
| Operating Cash Flow | (32.25M) | (46.52M) | (51.24M) | (35.5M) | (18.71M) |
| Capital Expenditures | (506K) | (1.62M) | (1.23M) | (268K) | (88K) |
| Acquisitions (Net) | 0 | (851K) | 0 | 0 | 0 |
| Purchases of Investments | 0 | (73.82M) | (73.26M) | (58.72M) | (33.97M) |
| Sales of Investments | 0 | 3M | 104.35M | 77.55M | 26.75M |
| Other Investing Activities | 0 | 851K | 0 | 1.25M | 278K |
| Investing Cash Flow | (506K) | (72.44M) | 29.86M | 19.81M | (7.03M) |
| Debt Repayment | (2.85M) | 29.57M | 0 | (5M) | (20.72M) |
| Common Stock Issued | 73.65M | 317K | 395K | 18.63M | 61.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 26K | (886K) | (162K) | (47K) | (59K) |
| Financing Cash Flow | 77.15M | 29.01M | 233K | 13.59M | 40.3M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 44.4M | (89.95M) | (21.14M) | (2.1M) | 14.56M |
| Free Cash Flow | (32.75M) | (48.13M) | (52.47M) | (35.76M) | (18.8M) |
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.